Search research articles
Contact Us
Filters
Showing results (1-10 of 233) with videos related to
Page
of 24
Sort By:
Therapie
|
April 11, 2015
Addiction, experimental models and neurobiological mechanisms
Régis Bordet
Therapie
|
February 16, 2021
Contributions of animal models of cognitive disorders to neuropsychopharmacology
Julie Deguil, Régis Bordet
Therapie
|
March 5, 2008
Neuroprotection: Present and future
Régis Bordet, Pierre Lestage, Brigitte Onteniente, et al.
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|
March 26, 2019
[Epidemiology of neurocognitive disorders in France]
Michaël Rochoy, Emmanuel Chazard, Régis Bordet
Psychopharmacology
|
July 28, 2010
Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model
Kévin Marche, Thierry Danel, Régis Bordet
Therapie
|
August 13, 2009
Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease
Philippe Truffinet, Régis Bordet, Joël Ménard
Medical Hypotheses
|
March 23, 2007
The strange case of Dr HDL and Mr HDL: does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP?
Patrick Duriez, Régis Bordet, Pascal Berthelot
Therapie
|
March 14, 2007
Medical pharmacology: from review to planning
Régis Bordet, Pascale Jolliet, Patrice Jaillon
Therapie
|
November 1, 2012
Personalized Medicine: how to Switch from the Concept to the Integration into the Clinical Development Plan to Obtain Marketing Authorization
Laurent Becquemont, Régis Bordet, Dominic Cellier, et al.
Behavioural Brain Research
|
January 18, 2011
Brain ischemia changes the long term response to antidepressant drugs in mice
Dominique Deplanque, Venugopal Reddy Venna, Régis Bordet
Page
of 24
Search research articles
Search
Showing results (1-10 of 233) with videos related to
Sort By:
Page
of 24
Therapie
|
April 11, 2015
Addiction, experimental models and neurobiological mechanisms
Régis Bordet
Therapie
|
February 16, 2021
Contributions of animal models of cognitive disorders to neuropsychopharmacology
Julie Deguil, Régis Bordet
Therapie
|
March 5, 2008
Neuroprotection: Present and future
Régis Bordet, Pierre Lestage, Brigitte Onteniente, et al.
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|
March 26, 2019
[Epidemiology of neurocognitive disorders in France]
Michaël Rochoy, Emmanuel Chazard, Régis Bordet
Psychopharmacology
|
July 28, 2010
Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model
Kévin Marche, Thierry Danel, Régis Bordet
Therapie
|
August 13, 2009
Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease
Philippe Truffinet, Régis Bordet, Joël Ménard
Medical Hypotheses
|
March 23, 2007
The strange case of Dr HDL and Mr HDL: does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP?
Patrick Duriez, Régis Bordet, Pascal Berthelot
Therapie
|
March 14, 2007
Medical pharmacology: from review to planning
Régis Bordet, Pascale Jolliet, Patrice Jaillon
Therapie
|
November 1, 2012
Personalized Medicine: how to Switch from the Concept to the Integration into the Clinical Development Plan to Obtain Marketing Authorization
Laurent Becquemont, Régis Bordet, Dominic Cellier, et al.
Behavioural Brain Research
|
January 18, 2011
Brain ischemia changes the long term response to antidepressant drugs in mice
Dominique Deplanque, Venugopal Reddy Venna, Régis Bordet
Page
of 24